Gene · 3802
Papers2,190
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,190
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-omics characterization of a scoring system to quantify hypoxia patterns in patients with head and neck squamous cell carcinoma. | J Transl Med | 2023 | 36627705 | PubTator, text mining | PubMed |
| Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. | Cancer Commun (Lond) | 2023 | 36585761 | PubTator, text mining | PubMed |
| KIR signaling is regulated by electrostatic interaction of its cytosolic tail with the plasma membrane despite being neutral polyampholyte. | Proc Natl Acad Sci U S A | 2023 | 36574700 | PubTator, text mining | PubMed |
| Software update: Interpreting killer-cell immunoglobulin-like receptors from whole genome sequence data with PING. | HLA | 2023 | 36565030 | PubTator, text mining | PubMed |
| Relationship between KIR genotypes and HLA-ligands with SARS-CoV-2 infection in the Saudi population. | J King Saud Univ Sci | 2023 | 36338940 | PubTator, text mining | PubMed |
| Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. | Cancer Immunol Immunother | 2023 | 36261539 | PubTator, text mining | PubMed |
| Local immune recognition of trophoblast in early human pregnancy: controversies and questions. | Nat Rev Immunol | 2023 | 36192648 | PubTator, text mining | PubMed |
| Multiomics analyses and machine learning of nuclear receptor coactivator 6 reveal its essential role in hepatocellular carcinoma. | Cancer Sci | 2023 | 36086920 | PubTator, text mining | PubMed |
| Killer cell immunoglobulin-like receptor (KIR) gene contents: Are they associated with cervical cancer? | J Med Virol | 2023 | 35593263 | PubTator, text mining | PubMed |
| The role of extravillous trophoblasts and uterine NK cells in vascular remodeling during pregnancy. | Front Immunol | 2022 | 37408837 | PubTator, text mining | PubMed |
| Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. | Front Oncol | 2022 | 37078002 | PubTator, text mining | PubMed |
| Decoding the diversity of killer immunoglobulin-like receptors by deep sequencing and a high-resolution imputation method. | Cell Genom | 2022 | 36777335 | PubTator, text mining | PubMed |
| Association of iKIR-mismatch model and donor aKIRs with better outcome in haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. | Front Immunol | 2022 | 36761162 | PubTator, text mining | PubMed |
| NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions. | Front Immunol | 2022 | 36741396 | PubTator, text mining | PubMed |
| Uterine NK cells underexpress KIR2DL1/S1 and LILRB1 in reproductive failure. | Front Immunol | 2022 | 36713400 | PubTator, text mining | PubMed |
| Single cell RNA sequencing research in maternal fetal interface. | Front Cell Dev Biol | 2022 | 36704195 | PubTator, text mining | PubMed |
| Contribution of natural killer cells in innate immunity against colorectal cancer. | Front Oncol | 2022 | 36686835 | PubTator, text mining | PubMed |
| Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells. | Front Immunol | 2022 | 36685552 | PubTator, text mining | PubMed |
| Natural Killer Cell Receptors and Endometriosis: A Systematic Review. | Int J Mol Sci | 2022 | 36613776 | PubTator, text mining | PubMed |
| Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. | Int J Mol Sci | 2022 | 36613644 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3802/papers?page=13